Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

Haematologica

Volumn 96, Issue 1, 2011, Pages 167-170

  Elena, Chiara ^a   Passamonti, Francesco ^a   Rumi, Elisa ^a   Malcovati, Luca ^a   Arcaini, Luca ^a   Boveri, Emanuela ^a   Merli, Michele ^a   Pietra, Daniela ^a   Pascutto, Cristiana ^a   Lazzarin, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Leukemia; MPL; Myelofibrosis; Prognosis; Transfusion JAK2

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELOID METAPLASIA; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PRIMARY MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 78650989990     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031831     Document Type: Article

References (24)

1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.
2. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 2006;3(7):e270.
3. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141-9.
4. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137(3):244-7.
5. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosomenegative myeloproliferative neoplasms. Blood.115(14):2882-90.
6. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-14.
7. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.
8. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-70.
9. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
10. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood.115(9):1703-8.
11. Morel P, Duhamel A, Hivert B, Stalniekiewicz L, Demory JL, Dupriez B. Identification during the follow-up of timedependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood.115(22):4350-5.
12. Cervantes F, Alvarez-Larran A, Hernandez- Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127(4):399-403.
13. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-9.
14. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22(3):424-31.
15. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158-64.
16. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009;84(5):265-7.
17. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis - prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85(1):14-7.
18. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, et al. What are RBCtransfusion- dependence and -independence? Leuk Res. 2010 Aug 5. [Epub ahead of print]
19. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-7.
20. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-8.
21. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
22. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110 (2):485-9.
23. Rumi E, Passamonti F, Arcaini L, Bernasconi P, Elena C, Pietra D, et al. Molecular remission after allo-SCT in a patient with postessential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant.45(4):798-800.
24. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107(5):2098-100.